{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:36:18Z","timestamp":1781825778311,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clinbiochem.2020.03.013","type":"journal-article","created":{"date-parts":[[2020,3,22]],"date-time":"2020-03-22T10:16:34Z","timestamp":1584872194000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction"],"prefix":"10.1016","volume":"80","author":[{"given":"Andreas","family":"Sand\u00f8","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Eugen-Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Kelb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Saunam\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Holmvang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frants","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Henrik","family":"Tilsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"H\u00f8fsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Helqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9351","key":"10.1016\/j.clinbiochem.2020.03.013_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","article-title":"Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials","volume":"361","author":"Keeley","year":"2003","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.clinbiochem.2020.03.013_b0010","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.109.873224","article-title":"Primary angioplasty versus fibrinolysis in acute myocardial infarction: long-term follow-up in the Danish acute myocardial infarction 2 trial","volume":"121","author":"Nielsen","year":"2010","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.clinbiochem.2020.03.013_b0015","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jacc.2014.08.037","article-title":"Short- and long-term cause of death in patients treated with primary PCI for STEMI","volume":"64","author":"Pedersen","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0020","doi-asserted-by":"crossref","unstructured":"Y. Yamashita, H. Shiomi, T. Morimoto et al. Cardiac and Noncardiac Causes of Long-Term Mortality in ST-Segment-Elevation Acute Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention. Circ. Cardiovasc. Qual. Outcomes (2017);10(1). https:\/\/doi.org\/10.1161\/circoutcomes.116.002790.","DOI":"10.1161\/CIRCOUTCOMES.116.002790"},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0025","doi-asserted-by":"crossref","unstructured":"Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet (1994);343(8893):311-322.","DOI":"10.1016\/S0140-6736(94)91161-4"},{"issue":"19","key":"10.1016\/j.clinbiochem.2020.03.013_b0030","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/01.CIR.101.19.2239","article-title":"Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years","volume":"101","author":"Thiemann","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1741-7015-12-80","article-title":"Risk stratification in emergency patients by copeptin","volume":"12","author":"Iversen","year":"2014","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.clinbiochem.2020.03.013_b0040","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/clc.4960240708","article-title":"A double-blind, multicentered study comparing the accuracy of diagnostic markers to predict short- and long-term clinical events and their utility in patients presenting with chest pain","volume":"24","author":"Fromm","year":"2001","journal-title":"Clin. Cardiol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.03.013_b0045","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jcrc.2012.12.001","article-title":"Improving risk classification of critical illness with biomarkers: a simulation study","volume":"28","author":"Seymour","year":"2013","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1186\/s13054-015-1098-z","article-title":"Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study","volume":"19","author":"Schuetz","year":"2015","journal-title":"Crit. Care"},{"issue":"10","key":"10.1016\/j.clinbiochem.2020.03.013_b0055","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1097\/01.CCM.0000284509.23439.5B","article-title":"N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients","volume":"35","author":"Meyer","year":"2007","journal-title":"Crit .Care Med."},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0060","doi-asserted-by":"crossref","unstructured":"N.A. Sorensen, G. Donmez J.T. Neumann, et al. diagnostic value of soluble urokinase-type plasminogen activator receptor in addition to high-sensitivity troponin i in early diagnosis of acute myocardial infarction, Biomolecules (2019);9(3). doi: 10.3390\/biom9030108.","DOI":"10.3390\/biom9030108"},{"issue":"4","key":"10.1016\/j.clinbiochem.2020.03.013_b0065","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/cc11434","article-title":"Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study","volume":"16","author":"Haupt","year":"2012","journal-title":"Crit. Care"},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.03.013_b0070","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ijcard.2012.03.040","article-title":"CRP and suPAR are differently related to anthropometry and subclinical organ damage","volume":"167","author":"Lyngbaek","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.03.013_b0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Eugen-Olsen","year":"2010","journal-title":"J. Intern. Med."},{"issue":"20","key":"10.1016\/j.clinbiochem.2020.03.013_b0080","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble urokinase receptor and chronic kidney disease","volume":"373","author":"Hayek","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.03.013_b0085","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001118","article-title":"Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events","volume":"3","author":"Eapen","year":"2014","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"10.1016\/j.clinbiochem.2020.03.013_b0090","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00134-013-3056-z","article-title":"Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission","volume":"39","author":"Suberviola","year":"2013","journal-title":"Intensive Care Med.."},{"issue":"11","key":"10.1016\/j.clinbiochem.2020.03.013_b0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/emermed-2015-205444","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study","volume":"33","author":"Rasmussen","year":"2016","journal-title":"Emerg. Med. J."},{"issue":"10","key":"10.1016\/j.clinbiochem.2020.03.013_b0100","first-page":"A5146","article-title":"suPAR as a biomarker for risk of readmission and mortality in the acute medical setting","volume":"62","author":"Nayak","year":"2015","journal-title":"Dan Med. J."},{"issue":"Suppl 1","key":"10.1016\/j.clinbiochem.2020.03.013_b0105","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1186\/1757-7241-23-S1-A31","article-title":"SuPAR - A future prognostic biomarker in emergency medicine","volume":"23","author":"\u00d8stervig","year":"2015","journal-title":"Scandin. J. Trauma, Resuscit. Emerg. Med."},{"issue":"6","key":"10.1016\/j.clinbiochem.2020.03.013_b0110","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.ijcard.2012.07.018","article-title":"Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score","volume":"167","author":"Lyngbaek","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2020.03.013_b0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/hr.2015.22","article-title":"Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years","volume":"38","author":"Botha","year":"2015","journal-title":"Hypertens. Res."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.03.013_b0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2011.01.049","article-title":"Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events","volume":"216","author":"Sehestedt","year":"2011","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.clinbiochem.2020.03.013_b0125","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.amjcard.2012.08.008","article-title":"Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention","volume":"110","author":"Lyngbaek","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.03.013_b0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ahj.2015.02.004","volume":"169","author":"Hofsten","year":"2015","journal-title":"Am. Heart. J."},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0135","unstructured":"ViroGates A\/S. SuPARnostic enzyme immunoassay for quantitative determination of soluble urokinase plasminogen activator receptor in human plasma. Available at: https:\/\/www.suparnostic.com\/images\/PI_008_v6.3_MAR_2019_20190305_AUTO_Flex_ELISA_IFU.pdf. Accessed on June 5, 2019. ."},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.03.013_b0140","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1911481","article-title":"Soluble urokinase receptor and acute kidney injury","volume":"382","author":"Hayek","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.03.013_b0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004425","article-title":"Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score","volume":"4","author":"Fox","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0150","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijcard.2015.03.041","article-title":"Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population","volume":"184","author":"Botha","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.03.013_b0155","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2011.10.039","article-title":"Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study","volume":"220","author":"Persson","year":"2012","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.03.013_b0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2014.08.035","article-title":"Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects","volume":"237","author":"Sorensen","year":"2014","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.clinbiochem.2020.03.013_b0165","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1007\/s00392-019-01475-1","article-title":"Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction","volume":"108","author":"S\u00f6rensen","year":"2019","journal-title":"Clin. Res. Cardiol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2020.03.013_b0170","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/eci.12785","article-title":"Multibiomarker analysis in patients with acute myocardial infarction","volume":"47","author":"Schernthaner","year":"2017","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.clinbiochem.2020.03.013_b0175","unstructured":"S. Hayek Salim, Y-A, Ko, M. Awad et al. Abstract 15077: SuPAR Predicts Cardiovascular Outcomes in Heart Failure Independently of High Sensitivity Troponin I. Circulation (2016);134(suppl_1):A15077-A15077. doi: 10.1161\/circ.134.suppl_1.15077."},{"issue":"4","key":"10.1016\/j.clinbiochem.2020.03.013_b0180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ejhf.49","article-title":"Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation","volume":"16","author":"Borne","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.clinbiochem.2020.03.013_b0185","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1373\/clinchem.2013.203778","article-title":"Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain","volume":"59","author":"Lyngbaek","year":"2013","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.03.013_b0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/STROKEAHA.113.003305","article-title":"Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease","volume":"45","author":"Persson","year":"2014","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.clinbiochem.2020.03.013_b0195","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/blood.V96.13.4091","article-title":"Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection","volume":"96","author":"Sidenius","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clinbiochem.2020.03.013_b0200","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00134-012-2613-1","article-title":"Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review","volume":"38","author":"Backes","year":"2012","journal-title":"Intensive Care Med."},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.03.013_b0205","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1478-3231.2011.02665.x","article-title":"Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis","volume":"32","author":"Zimmermann","year":"2012","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.clinbiochem.2020.03.013_b0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/172460080101600402","article-title":"Soluble urokinase plasminogen activator receptor measurements: influence of sample handling","volume":"16","author":"Riisbro","year":"2001","journal-title":"Int. J. Biol. Markers"},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.03.013_b0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jmv.21114","article-title":"Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy","volume":"80","author":"Andersen","year":"2008","journal-title":"J. Med. Virol."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930596X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930596X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:55:20Z","timestamp":1757865320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201930596X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":43,"alternative-id":["S000991201930596X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.03.013","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}